CDK12 and prostate carcinoma: A recent study has suggested that CDK12 can regulate AR's alternative splicing through RNA Pol II phosphorylation, and the loss of CDK12 may lead to resistance of prostate cancer cells to androgen receptor pathway inhibitors (ARSIs).46